Association between serum uric acid and renal outcome in patients with biopsy-confirmed diabetic nephropathy

Yutong Zou; Lijun Zhao; Junlin Zhang; Yiting Wang; Yucheng Wu; Honghong Ren; Tingli Wang; Rui Zhang; Jiali Wang; Yuancheng Zhao; Chunmei Qin; Huan Xu; Lin Li; Zhonglin Chai; Mark E. Cooper; Nanwei Tong; Fang Liu

doi:10.1530/EC-21-0307

Association between serum uric acid and renal outcome in patients with biopsy-confirmed diabetic nephropathy

Yutong Zou, Lijun Zhao, Junlin Zhang, Yiting Wang, Yucheng Wu, Honghong Ren, Tingli Wang, Rui Zhang, Jiali Wang, Yuancheng Zhao, Chunmei Qin, Huan Xu, Lin Li, Zhonglin Chai, Mark E. Cooper, Nanwei Tong, Fang Liu

Diabetes

Research output: Contribution to journal › Article › Research › peer-review

4 Citations (Scopus)

Abstract

Objective: To investigate the relationship between serum uric acid (SUA) level and renal outcome in patients with type 2 diabetes mellitus (T2DM) and diabetic nephropathy (DN). Methods: A total of 393 Chinese patients with T2DM and biopsy-proven DN and followed at least 1 year were enrolled in this study. Patients were stratified by the quartiles of baseline level of SUA: Q1 group: 286.02 ± 46.66 μmol/L (n = 98); Q2 group: 358.23 ± 14.03 μmol/L (n = 99); Q3 group: 405.50 ± 14.59 μmol/L (n = 98) and Q4 group: 499.14 ± 56.97μmol/L (n = 98). Renal outcome was defined by progression to end-stage renal disease (ESRD). Kaplan–Meier survival analysis and Cox proportional hazards model were used to analyze the association between SUA quartiles and the renal outcomes. Results: During the median 3-year follow-up period, there were 173 ESRD outcome events (44.02%). No significant difference between SUA level and the risk of progression of DN (P = 0.747) was shown in the Kaplan–Meier survival analysis. In multivariable-adjusted model, hazard ratios for developing ESRD were 1.364 (0.621–2.992; P = 0.439), 1.518 (0.768–3.002; P = 0.230) and 1.411 (0.706–2.821; P = 0.330) for the Q2, Q3 and Q4, respectively, in comparison with the Q1 (P = 0.652). Conclusions: No significant association between SUA level and renal outcome of ESRD in Chinese patients with T2DM and DN was found in our study. Besides, the role of uric acid-lowering therapy in delaying DN progression and improving ESRD outcome had not yet been proven. Further study was needed to clarify the renal benefit of the uric acid-lowering therapy in the treatment of DN.

Original language	English
Pages (from-to)	1299-1306
Number of pages	8
Journal	Endocrine Connections
Volume	10
Issue number	10
DOIs	https://doi.org/10.1530/EC-21-0307
Publication status	Published - Oct 2021

Keywords

Diabetic nephropathy
Renal outcome
Serum uric acid
Type 2 diabetes mellitus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1530/EC-21-0307Licence: CC BY

Cite this

@article{a91a1d205e0447d781080698da2a7136,

title = "Association between serum uric acid and renal outcome in patients with biopsy-confirmed diabetic nephropathy",

abstract = "Objective: To investigate the relationship between serum uric acid (SUA) level and renal outcome in patients with type 2 diabetes mellitus (T2DM) and diabetic nephropathy (DN). Methods: A total of 393 Chinese patients with T2DM and biopsy-proven DN and followed at least 1 year were enrolled in this study. Patients were stratified by the quartiles of baseline level of SUA: Q1 group: 286.02 ± 46.66 μmol/L (n = 98); Q2 group: 358.23 ± 14.03 μmol/L (n = 99); Q3 group: 405.50 ± 14.59 μmol/L (n = 98) and Q4 group: 499.14 ± 56.97μmol/L (n = 98). Renal outcome was defined by progression to end-stage renal disease (ESRD). Kaplan–Meier survival analysis and Cox proportional hazards model were used to analyze the association between SUA quartiles and the renal outcomes. Results: During the median 3-year follow-up period, there were 173 ESRD outcome events (44.02%). No significant difference between SUA level and the risk of progression of DN (P = 0.747) was shown in the Kaplan–Meier survival analysis. In multivariable-adjusted model, hazard ratios for developing ESRD were 1.364 (0.621–2.992; P = 0.439), 1.518 (0.768–3.002; P = 0.230) and 1.411 (0.706–2.821; P = 0.330) for the Q2, Q3 and Q4, respectively, in comparison with the Q1 (P = 0.652). Conclusions: No significant association between SUA level and renal outcome of ESRD in Chinese patients with T2DM and DN was found in our study. Besides, the role of uric acid-lowering therapy in delaying DN progression and improving ESRD outcome had not yet been proven. Further study was needed to clarify the renal benefit of the uric acid-lowering therapy in the treatment of DN.",

keywords = "Diabetic nephropathy, Renal outcome, Serum uric acid, Type 2 diabetes mellitus",

author = "Yutong Zou and Lijun Zhao and Junlin Zhang and Yiting Wang and Yucheng Wu and Honghong Ren and Tingli Wang and Rui Zhang and Jiali Wang and Yuancheng Zhao and Chunmei Qin and Huan Xu and Lin Li and Zhonglin Chai and Cooper, {Mark E.} and Nanwei Tong and Fang Liu",

note = "Funding Information: This study was supported by the National Natural Science Foundation of China (Grant numbers 81970626 and 81670662); Key Research and Development Project of Sichuan Science and Technology Department (Grant number 19ZDYF1273). Publisher Copyright: {\textcopyright} 2021 The authors Published by Bioscientifica Ltd.",

year = "2021",

month = oct,

doi = "10.1530/EC-21-0307",

language = "English",

volume = "10",

pages = "1299--1306",

journal = "Endocrine Connections",

issn = "2049-3614",

publisher = "BioScientifica (Society for Endocrinology)",

number = "10",

}

TY - JOUR

T1 - Association between serum uric acid and renal outcome in patients with biopsy-confirmed diabetic nephropathy

AU - Zou, Yutong

AU - Zhao, Lijun

AU - Zhang, Junlin

AU - Wang, Yiting

AU - Wu, Yucheng

AU - Ren, Honghong

AU - Wang, Tingli

AU - Zhang, Rui

AU - Wang, Jiali

AU - Zhao, Yuancheng

AU - Qin, Chunmei

AU - Xu, Huan

AU - Li, Lin

AU - Chai, Zhonglin

AU - Cooper, Mark E.

AU - Tong, Nanwei

AU - Liu, Fang

N1 - Funding Information: This study was supported by the National Natural Science Foundation of China (Grant numbers 81970626 and 81670662); Key Research and Development Project of Sichuan Science and Technology Department (Grant number 19ZDYF1273). Publisher Copyright: © 2021 The authors Published by Bioscientifica Ltd.

PY - 2021/10

Y1 - 2021/10

N2 - Objective: To investigate the relationship between serum uric acid (SUA) level and renal outcome in patients with type 2 diabetes mellitus (T2DM) and diabetic nephropathy (DN). Methods: A total of 393 Chinese patients with T2DM and biopsy-proven DN and followed at least 1 year were enrolled in this study. Patients were stratified by the quartiles of baseline level of SUA: Q1 group: 286.02 ± 46.66 μmol/L (n = 98); Q2 group: 358.23 ± 14.03 μmol/L (n = 99); Q3 group: 405.50 ± 14.59 μmol/L (n = 98) and Q4 group: 499.14 ± 56.97μmol/L (n = 98). Renal outcome was defined by progression to end-stage renal disease (ESRD). Kaplan–Meier survival analysis and Cox proportional hazards model were used to analyze the association between SUA quartiles and the renal outcomes. Results: During the median 3-year follow-up period, there were 173 ESRD outcome events (44.02%). No significant difference between SUA level and the risk of progression of DN (P = 0.747) was shown in the Kaplan–Meier survival analysis. In multivariable-adjusted model, hazard ratios for developing ESRD were 1.364 (0.621–2.992; P = 0.439), 1.518 (0.768–3.002; P = 0.230) and 1.411 (0.706–2.821; P = 0.330) for the Q2, Q3 and Q4, respectively, in comparison with the Q1 (P = 0.652). Conclusions: No significant association between SUA level and renal outcome of ESRD in Chinese patients with T2DM and DN was found in our study. Besides, the role of uric acid-lowering therapy in delaying DN progression and improving ESRD outcome had not yet been proven. Further study was needed to clarify the renal benefit of the uric acid-lowering therapy in the treatment of DN.

AB - Objective: To investigate the relationship between serum uric acid (SUA) level and renal outcome in patients with type 2 diabetes mellitus (T2DM) and diabetic nephropathy (DN). Methods: A total of 393 Chinese patients with T2DM and biopsy-proven DN and followed at least 1 year were enrolled in this study. Patients were stratified by the quartiles of baseline level of SUA: Q1 group: 286.02 ± 46.66 μmol/L (n = 98); Q2 group: 358.23 ± 14.03 μmol/L (n = 99); Q3 group: 405.50 ± 14.59 μmol/L (n = 98) and Q4 group: 499.14 ± 56.97μmol/L (n = 98). Renal outcome was defined by progression to end-stage renal disease (ESRD). Kaplan–Meier survival analysis and Cox proportional hazards model were used to analyze the association between SUA quartiles and the renal outcomes. Results: During the median 3-year follow-up period, there were 173 ESRD outcome events (44.02%). No significant difference between SUA level and the risk of progression of DN (P = 0.747) was shown in the Kaplan–Meier survival analysis. In multivariable-adjusted model, hazard ratios for developing ESRD were 1.364 (0.621–2.992; P = 0.439), 1.518 (0.768–3.002; P = 0.230) and 1.411 (0.706–2.821; P = 0.330) for the Q2, Q3 and Q4, respectively, in comparison with the Q1 (P = 0.652). Conclusions: No significant association between SUA level and renal outcome of ESRD in Chinese patients with T2DM and DN was found in our study. Besides, the role of uric acid-lowering therapy in delaying DN progression and improving ESRD outcome had not yet been proven. Further study was needed to clarify the renal benefit of the uric acid-lowering therapy in the treatment of DN.

KW - Diabetic nephropathy

KW - Renal outcome

KW - Serum uric acid

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85118787340&partnerID=8YFLogxK

U2 - 10.1530/EC-21-0307

DO - 10.1530/EC-21-0307

M3 - Article

C2 - 34524970

AN - SCOPUS:85118787340

SN - 2049-3614

VL - 10

SP - 1299

EP - 1306

JO - Endocrine Connections

JF - Endocrine Connections

IS - 10

ER -

Association between serum uric acid and renal outcome in patients with biopsy-confirmed diabetic nephropathy

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this